Correlation between the quantitative intensity of HLA-Ⅰ gene and its antibody and the clinical transfusion effect of matching platelets
10.13303/j.cjbt.issn.1004-549x.2022.11.002
- VernacularTitle:HLA-Ⅰ类基因及其抗体定量强度与配型血小板临床输注效果的相关性
- Author:
Xinyu HUANG
1
;
Shu CHEN
1
;
Ying LIU
1
;
Bing ZHANG
1
;
Ji HE
1
;
Xianguo XU
1
;
Faming ZHU
1
Author Information
1. Zhejiang Blood Center, Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou 310052, China
- Publication Type:Journal Article
- Keywords:
platelet antibody strength;
genetically-matched platelets;
HLA;
mean fluorescence intensity;
platelet transfusion refractoriness;
corrected count increment
- From:
Chinese Journal of Blood Transfusion
2022;35(11):1101-1104
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To explore the influence of anti-HLA-Ⅰ with different mean fluorescence intensity (MFI) on the efficacy of HLA-A and -B gene matching platelet transfusion, so as to provide scientific data for clinical platelet gene matching transfusion strategy. 【Methods】 A total of 81 PTR patients had applied for HLA-Ⅰgene matched platelets from the platelet gene database established by our laboratory, and 28 (MFI <5 000) of them needed further avoiding of partial donor-specific antibodies and they were enrolled as the research subjects. According to the platelet MFI value of HLA-Ⅰ antibody-targeting antigen, they were divided into negative transfusion group (MFI <500) (group A) and positive transfusion groups (MFI≥500) ; the latter were further divided into group B (500≤MFI <1 000), group C (1 000≤MFI <3 000) and group D (MFI≥3 000) according to MFI value. Corrected count increment (CCI) in platelet count was used to compare the platelet transfusion effect in 4 groups. 【Results】 Among 28 platelet recipients with MFI <5 000, 19(67.86%) patients successfully received 72 effective transfusions. The first CCI (×109/L) in groups A, B, C and D were 10.27±7.46, 7.58±4.75 (P>0.05), 17.36±7.63 (P>0.05) and -0.77±2.30 (P<0.05), respectively. There was no statistical difference among group A, B and C. 【Conclusion】 The application of HLA-Ⅰ gene matching platelets in PTR patients can adjust the MFI threshold(<2 000) appropriately according to the patient′s condition without compromising the platelet transfusion effect.
